Early drug combo shows promise for high-risk leukemia patients
NCT ID NCT02518555
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 29 times
Summary
This study tested whether the drug ibrutinib, given with vaccines, can help people with early-stage but high-risk chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) live longer without their cancer getting worse. The trial included 42 participants who had not yet developed symptoms. The main goal was to see how many patients remained alive and cancer-free over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.